The DILITRAIN™  outsourced service makes early, high-acuity assessment of hepatotoxic risk cost-effective for smaller organizations and thereby brings new illumination to the challenge of reducing late-stage candidate attrition.  DILITRAIN™ results are generated on HµREL® microlivers, which in peer-reviewed studies have been shown to provide predictive sensitivity and accuracy superior to that of both 3D spheroidal primary hepatocyte cultures and hepatoma cell lines.

$975 per compound is the delivered cost for DILITRAIN™  data.  There is no minimum on the number of compounds a client may have tested at one time.  DILITRAIN™  is intended to be implemented at the early lead selection stage of preclinical discovery/development—i.e., at roughly the same time as such other basic panels as solubility and Herg assays—so as to minimize the production burden on synthetic chemistry.  DILITRAIN™  entails a 14-day repeat-dosing protocol with ATP readout on Days 2 and 14.  Total study turnaround time, from receipt of sample to data delivery, is 21 days.